

Moberg Derma AB - Company Description

Moberg Derma develops and commercializes innovative medical products with an attractive return potential and limited development risk, primarily within dermatology. Development programs are based on innovative drug delivery or combinations of proven compounds, which reduces development risk significantly.

Our vision is to become a fast growing specialty pharma company with a leading position in selected European markets. We develop and commercialize innovative products with a global footprint based on unique, patented concepts and established compounds.

Product portfolio

The first two products - for nail diseases and seborrheic dermatitis - are in registration phase as medical devices.

Product	Indication	Reg	Status
K101	Nail disorders	CE, IIa	Reg 2010
KPR (5 products)	Scalp disorders, Eczema/Dry skin	CE, IIa / Cosm.	Reg 2010
A-fizz	Anal Fissures	Drug	PII 2010
Limtop	Actinic Keratosis	Drug	Preclin
MOB-015	Confidential	Drug	PII 2010

K101

K101 has the potential to become a market leader in the treatment of nail diseases, including onychomycosis and nail psoriasis. Clinical phase III results (n = 493) demonstrated a strong efficacy and safety profile. The product has a rapid once-set, and is available in a consumer friendly once-daily application.



Source: Study SM13

Before treatment After 2 weeks After 3 months

KPR (Kaprolac® Product Range)

Clinically documented products which combine excellent hydration, keratolytic properties and normalizes the microenvironment. Kaprolac® product range include products for Seborrheic Eczema, Dandruff Shampoo, Cream for dry and sensitive skin, Foot spray and Cuticle Care

A-fizz

Anal fissures are common and painful. A-fizz use novel use and patented formulation of a proven compound which decreases tension of musculature and enables healing of chronic anal fissures with negligible side-effects. Effective pain relief and potential to target three indications: - Acute and Chronic Anal Fissures - *Proctalgia fugax* (anal spasms)

Limtop

A new imiquimod formulation with more than 100x better bioavailability than existing products, with the potential for a product with significantly reduced side-effects, shorter treatment time and maintained efficacy.

MOB-015

Potential to develop market leader with a novel topical therapy.

Partners and distributors

Moberg Derma collaborates with partners and distributors for commercialization. The company has licensed rights to its nail product to a leading OTC marketer in the Nordic Region and is in the process of closing several partnering deals. There is considerable interest in the company's project portfolio.

Management, Board of Directors and owners

The company has ten employees with solid expertise in pharmaceutical and business development. Peter Wolpert is CEO and Chairman is Ingemar Aldén (Mats Pettersson from April 2010).

The company is supported by leading dermatologists from Karolinska, Sahlgrenska and UCSF. Moberg Derma is owned by Östersjöstiftelsen, private investors, the management and founders. 115 MSEK has been raised to date. The company aims at an IPO at the OMX during 2011.

Speaker Profile

Peter Wolpert, CEO, Board member and Co-founder, MSc (Eng), MSc (Econ)

Peter Wolpert has worked as CEO, strategy consultant and entrepreneur in life sciences since 1997 and was previously a strategy consultant at McKinsey & Co. Mr. Wolpert is also the co-founder of Viscogel AB and serves as Board Director of Viscogel AB and Lipopeptide AB.

